Creating Regulatory Pathways for Personalized & Oncology-Focused mRNA Therapies in a Framework Built for Vaccines
- Understanding how personalized and patient-specific mRNA products are being approached by EMA and MHRA
- Learning from ongoing oncology-focused mRNA trials navigating the current patchwork of global expectations
- Discussing gaps in guidance for non-infectious mRNA indications and how companies are addressing them